Kodiak matches Regeneron’s Eylea in macular edema phase 3, lighting Beacon of hope after flop

Kodiak Sciences has bounced back from the failure of its eye disease drug candidate, noting that it has matched Regeneron and Bayer’s blockbuster Eylea in a phase 3 trial of macular edema due to retinal vein occlusion (RVO).